Sanofi
Sanofi, the French pharmaceutical manufacturer, said on Thursday that its first-quarter net income attributable to equity holders fell 43.2% to €1.13 billion ($1.21 billion) from last year's €2 billion. The figures are based on the International Financial Reporting Standards or IFRS. Earnings per share declined 43.1% to €0.91 from €1.60 a year ago. Business net income was €2.22 billion, compared to €2.70 billion last year. Business earnings per share were €1.78, compared to €2.16 last year. IFRS net sales grew 2.4% to €10.46 billion from last year's €10.22 billion. Sales growth was 6.7% at con...
DPA Breaking News
Tl;drLe vaccin Efluelda ne sera plus disponible en France.Sanofi impute ce retrait à un tarif de vente trop bas.Les autorités maintiennent une recommandation égale entre les vaccins.Sanofi promet de proposer son vaccin classique en remplacement.Le vaccin contre la grippe Efluelda, une prochaine absence sur le marché françaisEn raison de désaccords tarifaires, le laboratoire français Sanofi a annoncé le retrait prochain du vaccin contre la grippe Efluelda du marché français. Ce dernier n’étant pas jugé supérieur aux autres vaccins par les autorités, il ne justifie donc pas un prix plus élevé. U...
Actusante
French pharmaceutical and health-care company Sanofi posted a fourth-quarter loss on Thursday, despite higher net sales and compared to the prior year's profit. Further, the board proposed annual dividend of €3.76 ($4.05) per share, an increase of 5.6%. Looking ahead for fiscal 2024, Sanofi expects business earnings per share to remain roughly stable excluding the impact of an expected effective tax rate increase to 21%, and decrease low single-digit at constant exchange rates (CER) including the higher expected tax rate. Separately, the company announced the appointment of François-Xavier Rog...
DPA Breaking News
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら